NASDAQ:MGTA Magenta Therapeutics (MGTA) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free MGTA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.68▼$0.7650-Day Range$0.36▼$0.7652-Week Range$0.32▼$2.07Volume376,000 shsAverage Volume848,835 shsMarket Capitalization$42.44 millionP/E RatioN/ADividend YieldN/APrice Target$0.50 Stock AnalysisStock Analysis Get Magenta Therapeutics alerts: Email Address Magenta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside28.5% Downside$0.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.49 out of 5 starsMedical Sector913th out of 947 stocksBiotechnology Industry14th out of 17 stocks 1.0 Analyst's Opinion Consensus RatingMagenta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.50, Magenta Therapeutics has a forecasted downside of 28.5% from its current price of $0.70.Amount of Analyst CoverageMagenta Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MGTA. Previous Next 0.0 Dividend Strength Dividend YieldMagenta Therapeutics does not currently pay a dividend.Dividend GrowthMagenta Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMagenta Therapeutics has received a 74.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Magenta Therapeutics is -0.84. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Magenta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.18% of the stock of Magenta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.53% of the stock of Magenta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioMagenta Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Magenta Therapeutics Stock (NASDAQ:MGTA)Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy MGTA Stock News HeadlinesFebruary 23, 2024 | finanznachrichten.deTEOCO's new framework drives Zero Touch Operational Automation at Magenta TelekomFebruary 22, 2024 | finance.yahoo.comTEOCO's New Framework drives Zero Touch Operational Automation at Magenta TelecomMarch 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…February 16, 2024 | msn.comGerman streamer Joyn lands on Magenta TVFebruary 7, 2024 | macrumors.comT-Mobile Debuts 'Magenta Status' Rewards for SubscribersFebruary 7, 2024 | 9to5mac.comT-Mobile ramps up loyalty rewards with ‘Magenta Status’, here’s what’s includedFebruary 7, 2024 | stockhouse.comT-Mobile Customers Now Have "Magenta Status" - VIP Vibes with One-of-a-Kind Benefits Across Premium Brands and ServicesFebruary 3, 2024 | investing.comViking Therapeutics Inc (VKTX)March 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…January 31, 2024 | msn.comT-Mobile's Magenta Max Plan: Is It Really Worth Upgrading?November 29, 2023 | msn.comOperation Magenta: Kent Police issue update following Gosport Memorial Hospital investigationNovember 27, 2023 | msn.comMagenta’s Ellesmere Port extra care scheme celebrates sixth birthdayNovember 21, 2023 | health.usnews.comMagenta HallNovember 21, 2023 | msn.comMagenta Living collaborates with Welsh housing associationNovember 20, 2023 | msn.comMovie Review - Magenta Coal: Promising Series Crashlands At Tail EndNovember 16, 2023 | msn.com£3.6m invested into making Magenta Living houses energy efficientNovember 14, 2023 | msn.comEstate of Stan VanDerBeek, Experimental Filmmaker and ‘Agitator,' Joins Magenta PlainsNovember 14, 2023 | finance.yahoo.comFMR LLC Acquires New Stake in Magenta Therapeutics IncNovember 14, 2023 | msn.comMagenta Living customers complete new life skills programmeNovember 8, 2023 | msn.comMagenta Living launch new digital system to deal with damp and mouldOctober 30, 2023 | msn.com‘Magenta Coal’ lights up Netflix, soars to No. 1 in 24 hoursOctober 25, 2023 | msn.com'Magenta Coal's' unveiled cast: Late Busi Lurayi returns to Netflix dramaOctober 20, 2023 | bizjournals.comMore biotechs are shutting down as investors, executives clash over valuationsOctober 10, 2023 | finance.yahoo.comResults from Magenta Medical's US Early Feasibility Study of the World's Smallest and Most Powerful Heart Pump to be Highlighted at TCT 2023September 14, 2023 | finance.yahoo.comInsider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics IncSeptember 13, 2023 | money.usnews.comDianthus Therapeutics IncSeptember 11, 2023 | benzinga.comMagenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock SplitSee More Headlines Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 201-2700FaxN/AEmployees67Year FoundedN/APrice Target and Rating Average Stock Price Target$0.50 High Stock Price Target$0.50 Low Stock Price Target$0.50 Potential Upside/Downside-28.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.88% Return on Assets-57.27% Debt Debt-to-Equity RatioN/A Current Ratio19.49 Quick Ratio19.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book0.57Miscellaneous Outstanding Shares60,665,000Free Float51,456,000Market Cap$42.44 million OptionableNot Optionable Beta2.12 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 51)MBA, Pres, Chief Financial & Operating Officer and Treasurer Comp: $637.21kShan WuHead of Investor RelationsMr. Thomas W. Beetham J.D. (Age 53)MBA, Chief Legal Officer & Sec. Ms. Catherine MonaghanHead of Clinical Devel. OperationsMr. Jim HaneySr. Director of Investor RelationsKey CompetitorsOcuphire PharmaNASDAQ:OCUPGamida CellNASDAQ:GMDAFreeline TherapeuticsNASDAQ:FRLNMolecular TemplatesNASDAQ:MTEMInhibikase TherapeuticsNYSE:IKTView All Competitors MGTA Stock Analysis - Frequently Asked Questions Should I buy or sell Magenta Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGTA, but not buy additional shares or sell existing shares. View MGTA analyst ratings or view top-rated stocks. What is Magenta Therapeutics' stock price target for 2024? 1 brokers have issued twelve-month target prices for Magenta Therapeutics' shares. Their MGTA share price targets range from $0.50 to $0.50. On average, they predict the company's share price to reach $0.50 in the next year. This suggests that the stock has a possible downside of 28.5%. View analysts price targets for MGTA or view top-rated stocks among Wall Street analysts. How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) announced its earnings results on Thursday, November, 4th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.02. When did Magenta Therapeutics' stock split? Magenta Therapeutics's stock split on Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly created shares were issued to shareholders after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What is Jason Gardner's approval rating as Magenta Therapeutics' CEO? 3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP). When did Magenta Therapeutics IPO? (MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:MGTA) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.